等待开盘 11-18 09:30:00 美东时间
0.000
0.00%
The latest update is out from IC Enterra Yenilenebilir Enerji AS ( ($TR:ENTRA) ...
今天 14:48
Entrada Therapeutics announced the completion of Cohort 2 enrollment in the ELEVATE-45-201 Phase 1/2 study of ENTR-601-45 for Duchenne muscular dystrophy (DMD). The independent Data Monitoring Committee recommended advancing to Cohort 3 at a higher dose of 15 mg/kg. ENTR-601-45 is designed to treat DMD patients with exon 45 skipping mutations by promoting dystrophin production. Data from Cohort 2 is expected in H1 2027.
今天 08:00
IC Enterra Yenilenebilir Enerji AS ( ($TR:ENTRA) ) has issued an update. IC Ent...
11-14 00:44
ADENTRA ( ($TSE:ADEN) ) has shared an update. ADENTRA is one of North America’s...
11-09 21:17
Entrada Therapeutics reported progress on its clinical trials for Duchenne muscular dystrophy, including completion of open-label dosing in ELEVATE-44-201 Cohort 1 and positive safety results in ELEVATE-45-201 Cohort 1. The company expects to receive data from these trials by year-end 2026 and early 2027, respectively. Cash reserves of $193 million are expected to support operations into Q4 2027.
11-05 12:00
IC Enterra Yenilenebilir Enerji AS ( ($TR:ENTRA) ) has provided an update. IC İ...
10-30 14:49
IC Enterra Yenilenebilir Enerji AS ( ($TR:ENTRA) ) has shared an announcement. ...
10-15 14:29
An announcement from Entrada Therapeutics Inc ( ($TRDA) ) is now available. On ...
10-14 20:20
Entrada Therapeutics announced positive topline results from Cohort 1 of its Phase 1/2 ELEVATE-45-201 study for ENTR-601-45 in Duchenne muscular dystrophy (DMD) patients. The study met primary objectives of favorable safety and tolerability at a 5 mg/kg dose. Secondary objectives showed a 0.10% mean increase in dystrophin and 0.15% in exon skipping versus baseline. ENTR-601-45's dosing schedule is Q6W, offering a lower administration frequency co...
10-14 11:00
The latest update is out from IC Enterra Yenilenebilir Enerji AS ( ($TR:ENTRA) ...
10-05 14:44